Ostrowitzki, Susanne, Deptula, Dennis, Thurfjell, Lennart, Barkhof, Frederik, Bohrmann, Bernd, Brooks, David J., Klunk, William E., Ashford, Elizabeth, Yoo, Kisook, Xu, Zhi-Xin, Loetscher, Hansruedi, Santarelli, Luca

Background: Gantenerumab is a fully human anti-Aβ monoclonal antibody in clinical development for the treatment of Alzheimer disease (AD).; Objectives: To investigate whether treatment with gantenerumab leads to a measurable reduction in the level of Aβ amyloid in the brain and to elucidate the mechanism of amyloid reduction.; Design: A multicenter, randomized, double-blind, placebo-controlled, ascending-dose […]

Rinne, Juha O., Brooks, David J., Rossor, Martin N., Fox, Nick C., Bullock, Roger, Klunk, William E., Mathis, Chester A., Blennow, Kaj, Barakos, Jerome, Okello, Aren A., Rodriguez Martinez de Liano, Sofia, Liu, Enchi, Koller, Martin, Gregg, Keith M., Schenk, Dale, Black, Ronald, Grundman, Michael

Background: Carbon-11-labelled Pittsburgh compound B ((11)C-PiB) PET is a marker of cortical fibrillar amyloid-beta load in vivo. We used (11)C-PiB PET to investigate whether bapineuzumab, a humanised anti-amyloid-beta monoclonal antibody, would reduce cortical fibrillar amyloid-beta load in patients with Alzheimer’s disease.; Methods: Patients with mild-to-moderate Alzheimer’s disease were randomly assigned to receive intravenous bapineuzumab or […]

Rinne, Juha O., Frantzen, Janek, Leinonen, Ville, Lonnrot, Kimmo, Laakso, Aki, Virtanen, Kirsi A., Solin, Olof, Kotkansalo, Anna, Koivisto, Anne, Sajanti, Juha, Karppinen, Atte, Lehto, Hanna, Rummukainen, Jaana, Buckley, Chris, Smith, Adrian, Jones, Paul A., Sherwin, Paul, Farrar, Gill, McLain, Richard, Kailajarvi, Marita, Grachev, Igor D.

Unlabelled: BACKGOUND/OBJECTIVE: To determine the level of association between uptake of the amyloid positron emission tomography (PET) imaging agent [(18)F]flutemetamol and the level of amyloid-β measured by immunohistochemical and histochemical staining in a frontal cortical region biopsy site.; Methods: Seventeen patients with probable normal pressure hydrocephalus (NPH) underwent prospective [(18)F]flutemetamol PET and subsequent frontal cortical […]

Ossenkoppele, Rik, Prins, Niels D., Pijnenburg, Yolande A.L., Lemstra, Afina W., van der Flier, Wiesje M., Adriaanse, Sofie F., Windhorst, Albert D., Handels, Ron L.H., Wolfs, Claire A.G., Aalten, Pauline, Verhey, Frans R.J., Verbeek, Marcel M., van Buchem, Mark A., Hoekstra, Otto S., Lammertsma, Adriaan A., Scheltens, Philip, van Berckel, Bart N.M.

Background: [(11)C]Pittsburgh compound B ([(11)C]PIB) and [(18)F]-2-fluoro-2-deoxy-D-glucose ([(18)F]FDG) PET measure fibrillar amyloid-β load and glucose metabolism, respectively. We evaluated the impact of these tracers on the diagnostic process in a memory clinic population.; Methods: One hundred fifty-four patients underwent paired dynamic [(11)C]PIB and static [(18)F]FDG PET scans shortly after completing a standard dementia screening. Two-year […]

Mathis, Chester A., Kuller, Lewis H., Klunk, William E., Snitz, Beth E., Price, Julie C., Weissfeld, Lisa A., Rosario, Bedda L., Lopresti, Brian J., Saxton, Judith A., Aizenstein, Howard J., McDade, Eric M., Kamboh, M. Ilyas, DeKosky, Steven T., Lopez, Oscar L.

Objective: This study examined amyloid-β (Aβ) deposition in 190 nondemented subjects aged ≥82 years to determine the proportion of Aβ-positive scans and associations with cognition, apolipoprotein E (APOE) status, brain volume, and Ginkgo biloba (Gb) treatment.; Methods: Subjects who agreed to participate had a brain magnetic resonance imaging and positron emission tomography scan with (11) […]

Grundman, Michael, Pontecorvo, Michael J., Salloway, Stephen P., Doraiswamy, P. Murali, Fleisher, Adam S., Sadowsky, Carl H., Nair, Anil K., Siderowf, Andrew, Lu, Ming, Arora, Anupa K., Agbulos, Abigail, Flitter, Matthew L., Krautkramer, Michael J., Sarsour, Khaled, Skovronsky, Daniel M., Mintun, Mark A.

Florbetapir F18 has been approved by the Food and Drug Administration for in vivo assessment of amyloid pathology in patients undergoing evaluation for Alzheimer disease (AD). The aim of this study was to determine the impact of amyloid imaging on the diagnoses and management of patients undergoing evaluation for cognitive decline. Patients were recruited to […]

Bahar-Fuchs, Alex, Villemagne, Victor, Ong, Kevin, Chetélat, Gaël, Lamb, Fiona, Reininger, Cornelia B., Woodward, Michael, Rowe, Christopher C.

Assessment of disease biomarkers, particularly the in vivo assessment of amyloid-β (Aβ) burden with positron emission tomography (PET), is gradually becoming central to the diagnosis of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD). However, the incorporation of biomarker evidence to the diagnostic process is currently restricted mainly to research settings. The identification of […]